CRISPR-Cas9 Screening of Putative Checkpoint Inhibitors in αβT cells and γδ T cells

This project focuses in the discovery of novel checkpoint inhibitory molecules present in abT cells, as well as gdT cells. To do so, CRISPR-Cas9 will be used to screen multiple candidates of interest in these cells and test them functionally to pick out those candidates which seem most promising. Finally, these candidates will be further tested to understand their mechanism of action and their potential use in therapeutics as a new therapy or as a combination with already existing ones, such as PD1 blockade.

Contact 
Laia Gasull